Duplaquet, Leslie, So, Kevin, Li, Xinyue, Li, Yixiang, Singh, Shilpa, Wu, Xiaoli S., Qi, Jun, Somerville, Tim, Heiling, Hillary, Mazzola, Emanuele, Zoller, Thomas, Vakoc, Christopher R., Forrester, William, Abrams, Tinya, Niederst, Matt, Kadoch, Cigall and Oser, Matthew J. (2024) Regulation of POU2F3 by mSWI/SNF and the ncBAF complexes as a targetable dependency for POU2F3 and are Selective Targetable Dependencies for POU2F3-Positive Small Cell Lung Cancer. Cancer cell (42). pp. 1-18.

Abstract

~12% of SCLCs are marked by the lineage transcription factor POU2F3, which is essential in all POU2F3-positive SCLCs. Thus, approaches to directly or indirectly inhibit POU2F3 could lead to new therapeutic strategies for POU2F3-positive SCLCs. Here we use a positive selection screening strategy where endogenous POU2F3 is fused to the suicide gene DCK*. Cells that express endogenous POU2F3-DCK* are killed in the presence of the nucleoside analog BVdU and only cells that downregulate the POU2F3-DCK* fusion survive. Genome-wide CRISPR/Cas9 resistance screens with BVdU in POU2F3-DCK* cells uncovered that inactivation of SMARCD1 or BRD9, both components of the non-canonical BAF (ncBAF) complex, markedly downregulate endogenous POU2F3. We find that all POU2F3-positive SCLC cell lines relative to ASCL1-positive and NEUROD1-positive cell lines, are exquisitely sensitive to mSWI/SNF complex inhibition using SMARCA2/4 inhibitors; while pure non-neuroendocrine POU2F3-positive SCLC cell lines are highly sensitive to ncBAF complex inhibition using highly selective BRD9 degraders. Mechanistically, BRD9 binds and regulates POU2F3 target genes including POU2F3 itself. BRD9 degraders or SMARCA2/4 inhibitors robustly decrease accessibility of POU2F3 target genes effectively shutting off POU2F3 function. Moreover, BRD9 degraders or SMARCA2/4 inhibitors decrease tumor growth and increase survival of mice bearing non-neuroendocrine POU2F3 xenografts. This works shows that mSWI/SNF and ncBAF tightly regulate POU2F3 expression and activity and nominate mSWI/SNF or ncBAF inhibition as druggable therapeutic strategies to selectively target POU2F3-positive SCLCs.

Item Type:	Article
Date Deposited:	14 Aug 2024 00:46
Last Modified:	14 Aug 2024 00:46
URI:	https://oak.novartis.com/id/eprint/52517